Robert Russell Conley

Title: Innovations by Robert Russell Conley in Migraine Prevention

Introduction

Robert Russell Conley is an accomplished inventor based in Annapolis, MD (US). He has made significant contributions to the field of migraine treatment, particularly through his innovative approaches to medication usage. His work focuses on improving the quality of life for individuals suffering from chronic migraines.

Latest Patents

Conley holds a patent for the "Chronic nightly dosing of lasmiditan for migraine prevention." This invention addresses the chronic nightly use of lasmiditan, specifically targeting therapy-resistant migraines. These are defined as migraines that do not respond to two or more prior monotherapy and/or dual therapy treatment or prevention regimens. His patent represents a crucial advancement in the management of difficult-to-treat migraine cases.

Career Highlights

Conley is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovative healthcare solutions. His role at the company allows him to contribute to groundbreaking research and development in the field of migraine therapies. With a focus on patient-centered solutions, Conley’s work is pivotal in advancing treatment options for those affected by migraines.

Collaborations

Conley has collaborated with notable colleagues, including Kirk Willis Johnson and Gudarz Davar. These partnerships enhance the research and development process, fostering an environment of innovation and shared expertise.

Conclusion

Robert Russell Conley’s contributions to migraine prevention through his patent on lasmiditan dosing exemplify the impact of innovative thinking in healthcare. His work continues to pave the way for improved treatment options for individuals suffering from chronic migraines.